Works by Li, Chunze
Results: 54
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models.
- Published in:
- British Journal of Cancer, 2023, v. 129, n. 9, p. 1383, doi. 10.1038/s41416-023-02190-5
- By:
- Publication type:
- Article
Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development.
- Published in:
- Xenobiotica, 2024, v. 54, n. 8, p. 543, doi. 10.1080/00498254.2024.2351044
- By:
- Publication type:
- Article
Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species.
- Published in:
- Xenobiotica, 2024, v. 54, n. 8, p. 511, doi. 10.1080/00498254.2024.2345849
- By:
- Publication type:
- Article
Fixed Dosing Versus Body Size–Based Dosing of Therapeutic Peptides and Proteins in Adults.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Fixed Dosing Versus Body Size–Based Dosing of Therapeutic Peptides and Proteins in Adults.
- Published in:
- Journal of Clinical Pharmacology, 2012, v. 52, n. 1, p. 18, doi. 10.1177/0091270010388648
- By:
- Publication type:
- Article
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 6, p. 1, doi. 10.1111/cts.13825
- By:
- Publication type:
- Article
Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 3, p. 1, doi. 10.1111/cts.13759
- By:
- Publication type:
- Article
Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 12, p. 2744, doi. 10.1111/cts.13669
- By:
- Publication type:
- Article
Concentration QTc analysis of giredestrant: Overcoming QT/heart rate confounding in the presence of drug‐induced heart rate changes.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 5, p. 823, doi. 10.1111/cts.13491
- By:
- Publication type:
- Article
Pharmacokinetics of biologics in gastric cancer.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 4, p. 564, doi. 10.1111/cts.13474
- By:
- Publication type:
- Article
Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data.
- Published in:
- CTS: Clinical & Translational Science, 2019, v. 12, n. 5, p. 534, doi. 10.1111/cts.12649
- By:
- Publication type:
- Article
Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2017, v. 44, n. 6, p. 537, doi. 10.1007/s10928-017-9544-y
- By:
- Publication type:
- Article
Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 6, p. 1055, doi. 10.1002/psp4.13141
- By:
- Publication type:
- Article
Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 2, p. 234, doi. 10.1002/psp4.13073
- By:
- Publication type:
- Article
Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2020, v. 9, n. 1, p. 48, doi. 10.1002/psp4.12482
- By:
- Publication type:
- Article
Time‐to‐Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine‐Citrulline‐Monomethylauristatin E Antibody–Drug Conjugates.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2019, v. 8, n. 8, p. 606, doi. 10.1002/psp4.12442
- By:
- Publication type:
- Article
PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 89, doi. 10.1002/cpdd.176
- By:
- Publication type:
- Article
Discovery of a Potent, CNS-Penetrant Orexin Receptor Antagonist Based on an N, N-Disubstituted-1,4-diazepane Scaffold that Promotes Sleep in Rats.
- Published in:
- ChemMedChem, 2009, v. 4, n. 7, p. 1069, doi. 10.1002/cmdc.200900069
- By:
- Publication type:
- Article
Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates.
- Published in:
- Clinical Pharmacokinetics, 2015, v. 54, n. 1, p. 81, doi. 10.1007/s40262-014-0182-x
- By:
- Publication type:
- Article
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.
- Published in:
- Leukemia & Lymphoma, 2022, v. 63, n. 9, p. 2180, doi. 10.1080/10428194.2022.2057484
- By:
- Publication type:
- Article
Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
- Published in:
- Leukemia & Lymphoma, 2020, v. 61, n. 12, p. 2905, doi. 10.1080/10428194.2020.1795154
- By:
- Publication type:
- Article
Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
- Published in:
- Leukemia & Lymphoma, 2020, v. 61, n. 1, p. 56, doi. 10.1080/10428194.2019.1657575
- By:
- Publication type:
- Article
Oxidative Stress Responses and Gene Transcription of Mice under Chronic-Exposure to 2,6-Dichlorobenzoquinone.
- Published in:
- International Journal of Environmental Research & Public Health, 2022, v. 19, n. 21, p. 13801, doi. 10.3390/ijerph192113801
- By:
- Publication type:
- Article
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 844, doi. 10.1007/s10637-019-00832-1
- By:
- Publication type:
- Article
Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 3, p. 499, doi. 10.1007/s00280-021-04296-0
- By:
- Publication type:
- Article
Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2020, v. 86, n. 3, p. 347, doi. 10.1007/s00280-020-04119-8
- By:
- Publication type:
- Article
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
- Published in:
- 2018
- By:
- Publication type:
- journal article
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
- Published in:
- 2017
- By:
- Publication type:
- journal article
Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 72, n. 5, p. 1079, doi. 10.1007/s00280-013-2273-z
- By:
- Publication type:
- Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology.
- Published in:
- British Journal of Clinical Pharmacology, 2021, v. 87, n. 6, p. 2493, doi. 10.1111/bcp.14662
- By:
- Publication type:
- Article
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
- Published in:
- British Journal of Clinical Pharmacology, 2017, v. 83, n. 12, p. 2767, doi. 10.1111/bcp.13381
- By:
- Publication type:
- Article
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 8, p. 1096, doi. 10.1002/jcph.1855
- By:
- Publication type:
- Article
Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, p. S105, doi. 10.1002/jcph.1720
- By:
- Publication type:
- Article
Physiologically Based Pharmacokinetic Model‐Informed Drug Development for Polatuzumab Vedotin: Label for Drug‐Drug Interactions Without Dedicated Clinical Trials.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, p. S120, doi. 10.1002/jcph.1718
- By:
- Publication type:
- Article
Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, p. S105, doi. 10.1002/jcph.1720
- By:
- Publication type:
- Article
Physiologically Based Pharmacokinetic Model‐Informed Drug Development for Polatuzumab Vedotin: Label for Drug‐Drug Interactions Without Dedicated Clinical Trials.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, p. S120, doi. 10.1002/jcph.1718
- By:
- Publication type:
- Article
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 8, p. 3635, doi. 10.1007/s12325-022-02170-w
- By:
- Publication type:
- Article
Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 1, p. 598, doi. 10.1007/s12325-021-01919-z
- By:
- Publication type:
- Article
Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies.
- Published in:
- 2020
- By:
- Publication type:
- Report
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
- Published in:
- Pharmaceutical Research, 2020, v. 37, n. 12, p. 1, doi. 10.1007/s11095-020-02933-6
- By:
- Publication type:
- Article
A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory.
- Published in:
- Pharmaceutical Research, 2018, v. 35, n. 6, p. 1, doi. 10.1007/s11095-018-2403-8
- By:
- Publication type:
- Article